How Many Doses Vial TB-500? (Dosing & Storage Guide)

How Many Doses Vial TB-500? (Dosing & Storage Guide)

A single 5mg vial of TB-500 (Thymosin Beta-4) doesn't deliver a fixed number of doses—it delivers a fixed amount of peptide that you divide based on your protocol. Research teams working with tissue repair models typically reconstitute TB-500 at concentrations between 2mg/mL and 5mg/mL, meaning the same vial might yield two 2.5mg administrations during acute injury phases or ten 500mcg maintenance doses during recovery monitoring. The confusion comes from treating peptide vials like pre-measured pharmaceuticals when they're actually raw material requiring dilution math.

We've worked with research labs across immune modulation and regenerative biology studies for years. The single most common reconstitution error isn't contamination—it's dosing math that doesn't account for peptide loss during transfer, dead space in syringes, and overfill variability between manufacturing batches.

How many doses does a vial of TB-500 provide?

A 5mg vial of TB-500 provides 2–10 doses depending on your protocol's per-administration target: 2.5mg weekly protocols yield two doses per vial, 1mg protocols yield five doses, and 500mcg maintenance schedules yield ten doses. The number of doses is determined by dividing total peptide mass by your target dose per injection after accounting for reconstitution volume.

Understanding TB-500 Vial Concentrations and Reconstitution Math

TB-500 vials ship as lyophilised powder—a freeze-dried peptide that requires reconstitution with bacteriostatic water before use. Real Peptides supplies TB-500 Thymosin Beta-4 in 5mg, 10mg, and 20mg vial formats, each requiring precise dilution to achieve target concentrations for subcutaneous injection protocols. The relationship between vial size, bacteriostatic water volume, and final concentration determines how many doses vial TB-500 delivers per container.

Reconstitution math follows this formula: (total peptide mass in mg) ÷ (bacteriostatic water volume in mL) = concentration in mg/mL. A 5mg vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL concentration—meaning each 1mL draw contains 2.5mg TB-500. If your protocol calls for 2mg per administration, you'd draw 0.8mL per dose, yielding 2.5 doses per vial. Researchers often add 2mL–5mL water to 5mg vials depending on preferred injection volume: smaller volumes (2mL) create concentrated solutions requiring smaller injection volumes but demand precise measurement, while larger volumes (5mL) create dilute solutions that are easier to measure accurately but require larger subcutaneous injection volumes.

The practical constraint is syringe precision. Standard insulin syringes measure to 0.01mL increments, making concentrations below 1mg/mL difficult to dose accurately for protocols requiring sub-milligram precision. Most tissue repair research models use 2–5mg TB-500 per administration during loading phases and 500mcg–2mg during maintenance phases, which favors reconstitution volumes between 2mL–3mL for 5mg vials. Real Peptides includes Bacteriostatic Water with peptide orders to ensure sterile reconstitution without additional sourcing delays.

Dosing Schedules: Loading Phase vs Maintenance Phase Protocols

TB-500 research protocols typically follow a two-phase structure: loading phase (high-frequency, high-dose administrations to saturate tissue) and maintenance phase (lower-frequency administrations to sustain plasma levels). The number of doses per vial changes dramatically between phases because per-administration targets shift from 2–5mg down to 500mcg–2mg.

Loading phase protocols in musculoskeletal injury models commonly administer 2–5mg TB-500 twice weekly for 4–6 weeks. A 5mg vial at 2.5mg per dose yields exactly two administrations, meaning researchers require 8–12 vials to complete a standard loading protocol. A 10mg vial reconstituted with 4mL bacteriostatic water (yielding 2.5mg/mL) provides four 2.5mg doses, reducing vial count requirements by half. Maintenance phase protocols drop to 500mcg–2mg once weekly or biweekly, meaning a single 5mg vial reconstituted to 1mg/mL (5mL bacteriostatic water) yields five to ten maintenance doses depending on target amount.

The half-life of TB-500 is approximately 7–10 days in circulation, though tissue depot effects extend local activity beyond plasma clearance. This pharmacokinetic profile supports weekly or twice-weekly dosing rather than daily administration. Protocols attempting daily low-dose TB-500 (e.g., 200–500mcg/day) increase vial consumption without proportional benefit because tissue saturation plateaus—the receptor-mediated uptake in injured tissue has a ceiling that excess circulating peptide doesn't overcome. Researchers tracking collagen deposition and angiogenesis markers in tendon repair models consistently observe that 2mg twice weekly produces comparable histological outcomes to 5mg twice weekly, but with 60% lower peptide consumption per study.

Our experience across hundreds of research protocols shows that dose creep—gradually increasing per-administration amounts without recalculating vial yield—is the primary driver of unexpected peptide depletion mid-study. Establish your per-dose target before reconstitution and mark each vial with concentration and dose volume to prevent math errors during administration.

Storage, Stability, and Dose Yield: What Affects Usable Doses Per Vial

Lyophilised TB-500 before reconstitution is stable at −20°C for 24–36 months. Once reconstituted with bacteriostatic water, stability drops to 28 days at 2–8°C (standard refrigeration). This 28-day window is the functional constraint on how many doses vial TB-500 delivers—if your protocol requires ten 500mcg doses spaced weekly, a single 5mg vial covers the entire sequence. If your protocol requires two 2.5mg doses spaced three days apart, the remaining peptide in a larger vial format goes unused unless additional studies commence within the stability window.

Temperature excursions above 8°C cause irreversible denaturation of the 43-amino-acid peptide chain that constitutes Thymosin Beta-4. A vial left at room temperature (20–25°C) for 6–8 hours loses approximately 15–25% potency based on HPLC analysis of degraded samples. The degradation isn't visible—solution clarity remains unchanged, and no precipitate forms. Researchers assuming visual inspection confirms potency consistently underdose later administrations without realizing the peptide has partially denatured. Store reconstituted TB-500 in the main refrigerator compartment (not the door, where temperature fluctuates), and discard any vial exposed to ambient temperature for more than two hours.

Overfill variability between manufacturing batches means a vial labeled 5mg often contains 5.2–5.5mg to ensure no vial falls below label claim. This 4–10% overfill doesn't justify rounding up your dose count—treat it as a buffer against transfer loss and dead space in syringes. Standard 1mL insulin syringes retain approximately 0.02–0.03mL in the needle hub after injection (dead space), meaning each administration wastes 2–3% of the drawn volume. Across ten doses, dead space loss compounds to one full dose equivalent.

Real Peptides synthesizes TB-500 through solid-phase peptide synthesis with >98% purity verified by HPLC, ensuring that labeled mass reflects active peptide rather than excipients or degradation products. Lower-purity preparations (90–95%) contain truncated peptide fragments and synthesis byproducts that occupy mass without contributing biological activity—effectively reducing dose yield by the impurity percentage. A 5mg vial at 90% purity delivers 4.5mg active TB-500, cutting dose count by 10% compared to high-purity alternatives.

TB-500 Vial Size Comparison: Doses Per Container by Protocol Type

The table below shows how many doses vial TB-500 provides across common vial sizes and protocol phases. Reconstitution volumes are optimized for syringe precision (0.01mL resolution) and subcutaneous injection comfort (≤1mL per administration).

Loading phase dose counts assume 2.5mg per administration—the midpoint of the 2–5mg range observed in musculoskeletal repair research. Protocols using 5mg per dose cut these counts in half. Maintenance phase assumes weekly or biweekly administration schedules; daily micro-dosing protocols (200–500mcg/day) consume vials 5–7× faster without proportional benefit in most injury models.

Key Takeaways

• A 5mg TB-500 vial yields 2–10 doses depending on protocol phase: 2 doses at 2.5mg each (loading) or 10 doses at 500mcg each (maintenance).
• Reconstitution math determines concentration: divide total peptide mass (mg) by bacteriostatic water volume (mL) to get mg/mL, then divide target dose by concentration to get injection volume.
• Reconstituted TB-500 remains stable for 28 days at 2–8°C—plan vial sizes to match protocol duration within this window.
• Temperature excursions above 8°C cause irreversible potency loss that visual inspection cannot detect; store in main refrigerator compartment, never the door.
• Overfill (4–10% above label claim) and dead space loss (2–3% per injection) roughly cancel each other—dose counts in this guide account for both.
• TB-500 half-life of 7–10 days supports weekly or twice-weekly dosing; daily micro-dosing increases vial consumption without proportional tissue saturation benefit.

What If: TB-500 Dosing Scenarios

What If I Accidentally Left My Reconstituted TB-500 Out Overnight?

Discard the vial. Thymosin Beta-4 denatures at ambient temperature (20–25°C) within 6–8 hours, losing 15–25% potency based on HPLC degradation curves. The solution remains clear and shows no visible precipitate, so there's no way to visually confirm potency loss. Researchers who inject temperature-compromised peptide unknowingly underdose every subsequent administration, introducing confounding variables that invalidate study endpoints. The cost of replacing one vial is negligible compared to the cost of compromised data integrity across a multi-week protocol.

What If My Protocol Requires 3mg Per Dose But My Vial Is 5mg?

Reconstitute with 2mL bacteriostatic water to achieve 2.5mg/mL concentration, then draw 1.2mL per dose. A 5mg vial provides 1.67 doses at this target (1.2mL × 1.67 = 2mL total volume). You'll have 0.8mL remaining after the first dose—not enough for a second full 3mg administration. Upgrade to a 10mg vial reconstituted with 4mL bacteriostatic water (same 2.5mg/mL concentration) to yield 3.33 doses per container. Alternatively, adjust your protocol to 2.5mg per dose if literature supports equivalent outcomes—many tendon repair models show no histological difference between 2.5mg and 3mg twice weekly.

What If I'm Running a Multi-Subject Study—How Many Vials Do I Need?

Calculate total peptide required across all subjects and phases, then add 15% buffer for transfer loss and dosing errors. Example: 4 subjects, 8-week protocol (4 weeks loading at 2.5mg twice weekly + 4 weeks maintenance at 1mg weekly). Per subject: (2.5mg × 2 doses/week × 4 weeks) + (1mg × 1 dose/week × 4 weeks) = 20mg + 4mg = 24mg per subject. Total: 24mg × 4 subjects = 96mg. Add 15% buffer: 96mg × 1.15 = 110mg. Divide by vial size: 110mg ÷ 10mg/vial = 11 vials. Order twelve 10mg vials to ensure completion without mid-study reordering delays.

The Practical Truth About TB-500 Dose Yield

Here's the honest answer: most researchers overestimate how many doses vial TB-500 delivers because they calculate based on label mass and ignore the 28-day stability window. A 20mg vial theoretically provides forty 500mcg doses, but if your maintenance protocol spaces doses 10–14 days apart, you'll only use six to eight of those doses before the 28-day refrigerated stability limit expires. The remaining peptide isn't 'saved'—it's discarded. Vial size should match protocol duration within the stability window, not just match total peptide required across an entire study timeline.

The second overlooked factor is syringe dead space. Standard insulin syringes retain 0.02–0.03mL in the needle hub after injection—this volume contains peptide that never reaches the subject. Across ten doses, dead space loss equals one full dose. Researchers calculating dose yield from reconstitution volume without subtracting cumulative dead space run out of peptide one administration early and either underdose the final injection or extend the study to source additional vials.

Protocol adherence beats peptide excess every time. A 5mg vial used correctly across a tightly controlled two-week loading phase delivers better outcomes than a 20mg vial stretched across an inconsistent three-month protocol with sporadic dosing and temperature excursions. Dose yield isn't just about math—it's about matching vial format to study design and maintaining cold chain discipline from reconstitution through final administration. Real Peptides' commitment to >98% purity and verified overfill means the peptide mass on the label is what you actually inject, not an aspirational claim inflated by synthesis byproducts.

Your protocol determines how many doses vial TB-500 truly delivers. Calculate backward from per-administration targets and stability windows—not forward from label mass alone—and you'll eliminate the most common cause of mid-study peptide shortages.